全部产品

首页 / 常见产品 / 全部产品

CAS:1323633-98-2|Fluphenazine-d8

  • 产品货号:DT2025061227
  • 发布时间:2025-06-05
  • 产品CAS :1323633-98-2
  • 产品规格:mg(更多包装需求请咨询客服)
  • 产品纯度:≥98%
  • 产品货期:现货下单后48小时内发货,定制产品4-8周。
  • 运输条件:顺丰常规运输
询价
产品详情

货号:DT2025061227
CAS:1323633-98-2
规格:mg(更多包装需求请咨询客服)
纯度:≥98%
生产商:试剂家

生物活性:Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2[1][2][3][4][5][6].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Fluphenazine-d8 相关抗体:
xCT Antibody (YA006)
xCT Antibody (YA652)
DRD2 Antibody
Alpha-ENaC Antibody
Dopamine Receptor D3 Antibody (YA1742)
DOPA Decarboxylase Antibody (YA2428)
Dopamine Receptor D1 Antibody (YA3270)
CRMP2 Antibody (YA3370)
SLC12A1 Antibody (YA1403)
CRMP1 Antibody (YA1941)
CRMP5 Antibody (YA2497)
CRMP3 Antibody (YA2563)
CRMP4 Antibody (YA2777)
Torsin 1A Antibody (YA2935)
PITX3 Antibody (YA2974)
HMBS Antibody (YA3061)
分子量:445.57
Formula:C22H18D8F3N3OS
CAS 号:1323633-98-2
非标记 CAS:69-23-8
中文名称:氟奋乃静癸EP杂质B-d8
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (545 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Zhou X, et al. The neuroleptic drug, fluphenazine, blocks neuronal voltage-gated sodium channels. Brain Res. 2006;1106(1):72-81.
 [Content Brief]
[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[3]. Nazeam J, et al. Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and Pathogenesis: Retrospective Analysis of Sinigrin and ProlixinRX (Fluphenazine) Provides Off-Label Drug Candidates. SLAS Discov. 2020 Dec;25(10):1123-1140.
 [Content Brief]
[4]. Siragusa S, Bistas KG, Saadabadi A. Fluphenazine. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
 [Content Brief]
[5]. Davis JL, et al. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. JAMA. 1977 Nov 21;238(21):2291-2.
 [Content Brief]
[6]. Langwiński R, Niedzielski J. Narcotic analgesics and stereotyped behaviour in mice. Naunyn Schmiedebergs Arch Pharmacol. 1980 Jul;312(3):225-7.
 [Content Brief]
[7]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]

常见基团 common groups
Online message

在线留言

欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。

* 咨询产品
* 您的姓名
* 联系电话
留言内容
验证码
Related Products

相关产品